Association between methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and H‐type hypertension: A systematic review and meta‐analysis

Abstract Purpose The polymorphism of methylenetetrahydrofolate reductase ( MTHFR ) gene C677T has been linked to H‐type hypertension. But the conclusion remained controversial. To elucidate this issue, we performed a comprehensive meta‐analysis to analyze the MTHFR C677T polymorphism and H‐type hypertension. Materials and methods The English and Chinese databases were systematically searched to identify relevant studies until November 2020. RevMan 5.3 and Stata 12.0 software were used for meta‐analysis. The odds ratio (ORs) and 95% confidence intervals (95% CIs) were used to assess the relationship between the MTHFR C677T polymorphism and H‐type hypertension. Results A total of 14 studies involving 1769 cases and 1443 controls were included. The meta‐analysis results showed the association between MTHFR C677T polymorphism and H‐type hypertension with the homozygous codominant model (OR = 3.30, 95% CI = 1.94–5.60), heterozygous codominant model (OR = 2.34, 95% CI = 1.53–3.58), dominant model (OR = 1.79, 95% CI = 1.33–2.41), recessive model (OR = 2.70, 95% CI = 1.73–4.21),and the allelic model (OR = 1.82, 95% CI = 1.41–2.35). All p ‐values were less than 0.05. Therefore, MTHFR C677T polymorphism has a positive correlation with the risk of H‐type hypertension. Among them, TT mutation has the greatest impact on the activity of this enzyme, which causes Hcy to rise and leads to H‐type hypertension. Conclusion In summary, our results provide sufficient data to support the hypothesis that the MTHFR C677T polymorphism is related to H‐type hypertension susceptibility.